Cancer drug discovery has been and continues to be a process of ingenuity, serendip- ity, and dogged determination. In an effort to develop and discover better therapies against cancer, investigators all over the world have increased our knowledge of cell biology, biochemistry, and molecular biology. The goal has been to define therapeuti- cally exploitable differences between normal and malignant cells. The result has been an increased understanding of cellular and whole-organism biology and an increased respect for the flexibility and resiliency ofbiologically systems. Thus, as some new therapeutic targets have been defined and new therapeutic strategies have been attempted, so have some new biological hurdles resulting from tumor evasion of the intended therapeutic attack been discovered. Historically, anticancer drugs have originated from all available chemical sources. Synthetic molecules from the chemical industry, especially dyestuffs and warfare agents, and natural products from plants, microbes, and fungi have all been potential sources of pharmaceuticals, including anticancer agents. There is no shortage of molecules; the challenge has been and continues to be methods of identifying molecules that have the potential to be therapeutically important in human malignant disease. "Screening" remains the most important and most controversial method in cancer drug discovery. In vitro screens have generally focused on cytotoxicity and have identified several highly cytotoxic molecules. Other endpoints available in vitro are inhibition of proliferation, 3 inhibition of [ H]thymidine incorporation into DNA and various viability assays, based most frequently on dye exclusion or metabolism.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Vendeur : bmyguest books, Toronto, ON, Canada
Hardcover. Etat : Fine. First Edition. Hardcover, pictorial boards. 451 pages with the index. tetxtbook binding.We will state signed at the description section. we confirm they are signed via email or stated in the description box. - Specializing in academic, collectiblle and historically significant, providing the utmost quality and customer service satisfaction. For any questions feel free to email us. N° de réf. du vendeur 18010
Quantité disponible : 1 disponible(s)
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
Etat : New. In. N° de réf. du vendeur ria9780896034600_new
Quantité disponible : Plus de 20 disponibles
Vendeur : Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irlande
Etat : New. This volume provides state-of-the-art information on the discovery and testing of anticancer agents currently available for routine use, as well as the discovery, rationale for, and current status of potentially exciting new agents for cancer therapy. Editor(s): Teicher, Beverly A. Series: Cancer Drug Discovery and Development. Num Pages: 451 pages, 7 black & white illustrations, biography. BIC Classification: MBGR; MJCL2. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly; (UU) Undergraduate. Dimension: 254 x 178 x 25. Weight in Grams: 1021. . 1996. Hardback. . . . . N° de réf. du vendeur V9780896034600
Quantité disponible : 15 disponible(s)
Vendeur : moluna, Greven, Allemagne
Gebunden. Etat : New. N° de réf. du vendeur 458446205
Quantité disponible : Plus de 20 disponibles
Vendeur : Mispah books, Redhill, SURRE, Royaume-Uni
Hardcover. Etat : Like New. Like New. book. N° de réf. du vendeur ERICA75808960346075
Quantité disponible : 1 disponible(s)
Vendeur : Kennys Bookstore, Olney, MD, Etats-Unis
Etat : New. This volume provides state-of-the-art information on the discovery and testing of anticancer agents currently available for routine use, as well as the discovery, rationale for, and current status of potentially exciting new agents for cancer therapy. Editor(s): Teicher, Beverly A. Series: Cancer Drug Discovery and Development. Num Pages: 451 pages, 7 black & white illustrations, biography. BIC Classification: MBGR; MJCL2. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly; (UU) Undergraduate. Dimension: 254 x 178 x 25. Weight in Grams: 1021. . 1996. Hardback. . . . . Books ship from the US and Ireland. N° de réf. du vendeur V9780896034600
Quantité disponible : 15 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Buch. Etat : Neu. Neuware - Cancer drug discovery has been and continues to be a process of ingenuity, serendip ity, and dogged determination. In an effort to develop and discover better therapies against cancer, investigators all over the world have increased our knowledge of cell biology, biochemistry, and molecular biology. The goal has been to define therapeuti cally exploitable differences between normal and malignant cells. The result has been an increased understanding of cellular and whole-organism biology and an increased respect for the flexibility and resiliency ofbiologically systems. Thus, as some new therapeutic targets have been defined and new therapeutic strategies have been attempted, so have some new biological hurdles resulting from tumor evasion of the intended therapeutic attack been discovered. Historically, anticancer drugs have originated from all available chemical sources. Synthetic molecules from the chemical industry, especially dyestuffs and warfare agents, and natural products from plants, microbes, and fungi have all been potential sources of pharmaceuticals, including anticancer agents. There is no shortage of molecules; the challenge has been and continues to be methods of identifying molecules that have the potential to be therapeutically important in human malignant disease. 'Screening' remains the most important and most controversial method in cancer drug discovery. In vitro screens have generally focused on cytotoxicity and have identified several highly cytotoxic molecules. Other endpoints available in vitro are inhibition of proliferation, 3 inhibition of [ H]thymidine incorporation into DNA and various viability assays, based most frequently on dye exclusion or metabolism. N° de réf. du vendeur 9780896034600
Quantité disponible : 2 disponible(s)